ClinicalTrials.gov
ClinicalTrials.gov Menu

Double-blind Study in Paediatric Epileptic to Compare the Subject Preference for ESL Suspension Formulation With Alternative Flavours

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02021461
Recruitment Status : Completed
First Posted : December 27, 2013
Results First Posted : April 3, 2014
Last Update Posted : April 3, 2014
Sponsor:
Information provided by (Responsible Party):
Bial - Portela C S.A.

Brief Summary:
The purpose of this study is to investigate the taste preference in children of 3 different flavours of the ESL oral suspension.

Condition or disease Intervention/treatment Phase
Epilepsy Drug: ESL Banana taste Drug: ESL Grape taste Drug: ESL Tutti-Frutti taste Phase 2

Detailed Description:
Children between the age of 5 and <8 years who are patients of the participating investigators will be screened for participation in the study. This may be at a regularly planned visit or the investigators may invite children who would be suitable candidates. Children who agree to participate will be invited to come back to the clinic on a single Study Day and will be randomised to a particular sequence of flavours. On the Study Day, all children will be given 3 different flavoured samples of Eslicarbazepine acetate (ESL) oral suspension for tasting, in the sequence to which they were randomised, in a double-blind, standardized setting. Each sample will consist of 2.5 mL and is to be given with a spoon in a double-blind manner, and is not to be swallowed. After tasting and spitting out each sample the child will be asked to rate the taste on a 10 cm visual analogue scale incorporating a facial hedonic scale. At the end of the session, the child will also be asked which flavour they thought tasted the best and which tasted the worst, to assess overall taste. A follow-up telephone contact interview will be performed between 1 and 4 days after the Study Day to collect adverse event (AE) data.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 38 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Official Title: Double-blind Study in Paediatric Epileptic Subjects Aged From 5 to Less Than 8 Years to Compare the Subject Preference for ESL Suspension Formulation With Alternative Flavours
Study Start Date : December 2012
Actual Primary Completion Date : December 2012
Actual Study Completion Date : December 2012

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: ESL Banana taste
Subjects were to be enrolled until there were at least 30 evaluable subjects (of whom at least 60% were <7 years of age). Evaluable subjects were those who completed 3 Visual analogue scale (VAS), 1 for each of the 3 tasting steps with the 3 flavoured oral suspensions.
Drug: ESL Banana taste
oral suspension with Banana flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.
Other Name: Eslicarbazepine acetate (ESL)

Experimental: ESL Grape taste
Subjects were to be enrolled until there were at least 30 evaluable subjects (of whom at least 60% were <7 years of age). Evaluable subjects were those who completed 3 Visual analogue scale (VAS), 1 for each of the 3 tasting steps with the 3 flavoured oral suspensions.
Drug: ESL Grape taste
oral suspension with Grape flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.
Other Name: Eslicarbazepine acetate (ESL)

Experimental: ESL Tutti-Frutti taste
Subjects were to be enrolled until there were at least 30 evaluable subjects (of whom at least 60% were <7 years of age). Evaluable subjects were those who completed 3 Visual analogue scale (VAS), 1 for each of the 3 tasting steps with the 3 flavoured oral suspensions.
Drug: ESL Tutti-Frutti taste
oral suspension with Tutti-Frutti flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.
Other Name: Eslicarbazepine acetate (ESL)




Primary Outcome Measures :
  1. Assessment of Taste Preference [ Time Frame: single Study Day ]
    Subject preference for 3 flavours of the ESL oral suspension was assessed based on a measured score using a 0-10 cm (minimum and maximum measured values) Visual Analogue Scale (VAS). Higher values represent the stronger preference.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   5 Years to 8 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • A written informed consent form signed by the subject's parent(s) or guardian(s) and an assent form for any 7-year-old subjects signed by subjects.
  • Male or female, between the age of 5 to <8 years.
  • Diagnosed with partial-onset epilepsy.
  • Is considered, in the opinion of the investigator, to be able to make the required taste assessment.

Exclusion Criteria:

  • Uncontrolled cardiac, renal, hepatic, endocrine, gastrointestinal, metabolic, haematological, or oncology disorder.
  • Known hypersensitivity to carboxamide derivatives or tricyclic antidepressants.
  • Strong congestion, flu, or any other acute illness that could influence the child's sense of taste.
  • A known swallowing or taste perception problem.
  • Currently or previously treated with ESL.
  • Concomitant participation in another drug clinical trial.
  • Any other condition or circumstance that, in the opinion of the investigator, could compromise the subject's ability to comply with the study protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02021461


Locations
Romania
Dr. Bacos Cosma Medical Centre
Timisoara, Timis County, Romania, 300314
Psychiatry Clinical Hospital "Prof. Dr. Alexandru Obregia" - Department of Pediatric
Bucharest, Romania, 041914
Slovakia
Neurology Outpatient Clinic for children and adults
Bardejov, Slovakia, 08501
Sponsors and Collaborators
Bial - Portela C S.A.

Responsible Party: Bial - Portela C S.A.
ClinicalTrials.gov Identifier: NCT02021461     History of Changes
Other Study ID Numbers: BIA-2093-212
First Posted: December 27, 2013    Key Record Dates
Results First Posted: April 3, 2014
Last Update Posted: April 3, 2014
Last Verified: February 2014

Additional relevant MeSH terms:
Eslicarbazepine acetate
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action